News

Nanochon Wins BioHealth Capital Region 6th Annual Crab Trap Competition

Nanochon, a Washington, D.C. based company in the BioHealth Capital Region, applying novel materials to replicate bone and cartilage, and high-end 3-D printing to create an implant which can permanently repair debilitating joint injuries, was selected from five finalists as the company with the most commercial potential at the 6th Annual Crab Trap Competition. This year’s judges included industry leaders Sally Allain, Head, Johnson & Johnson Innovation – JLABS @ Washington, DC, Andrea Alms, Co-Fund Manager, BioHealth Capital Fund, Lora Green, Of Counsel, Wilson Sonsini, Goodrich & Rosati, Troy LeMaile-Stovall, Chief Executive Officer, TEDCO, Conley Jones, Senior Associate, Alexandria Venture Investments, John Newby, Chief Executive Officer, Virginia Biotechnology Association, and was moderated by Rich Bendis, President & CEO, BioHealth Innovation, Inc.

The Crab Trap, presented virtually for the second year in the row due to the pandemic, was held on September 29th in association with the 7th Annual BioHealth Capital Region and 4th Annual BioHealth Capital Region Investment Conference. Nanochon CEO, Benjamin Holmes, presented on his company’s implant, which acts as both cartilage replacement and tissue growth scaffold, and is designed to be custom 3-D printed for each patient. Nanochon joins previous Crab Trap winners, BrainScope (2020), Floreo (2019), Galen Robotics (2018), LifeSprout (2017) and Sonavex (2016).

“It is a true honor to win the BioHealth Capital Region Crab Trap this year. Being an entrepreneur, especially in life sciences, is a difficult journey. Being recognized by this panel of judges is an achievement we are proud of.” said Benjamin Holmes, Nanchon CEO. “When we first created Nanochon, we were not sure we would stay in the region long term. However, the area continues to grow and provide the support and ecosystem we need to succeed and grow too.”

In addition to Nanochone, the judges and virtual audience viewed four other finalists’ presentations: Hubly SurgicalLinshomRevalo, and VNTC.

“The companies who present as part of the Crab Trap every year continue to be remarkable with their visions for the future of BioHealth.” said Richard Bendis, BHI President & CEO. “Not only do we applaud Nanochon and all the finalists this year, but also all the competitors over the past six years of this event. They truly are the future of this industry.”

Click here for a replay of the 6th Annual Crab Trap Competition is available online by

Founded in 2016, the Crab Trap Competition focuses on companies in therapeutics, diagnostics, medical devices, healthcare services, e-health, mobile health, electronic medical records, health informatics, and biohealth cyber security.

Recent News

03/21/2025

Luna Labs to Expand Research and Development Operations in Charlottesville

Governor Glenn Youngkin today announced that Luna Labs USA, LLC, a product development company accelerating breakthrough solutions to multiple industries, will invest $200,000 to expand its operations in the City of Charlottesville. The company will create 20 new jobs. “Luna Labs’ expansion demonstrates Virginia’s ability to cultivate and retain innovative technology companies,” said Governor Glenn Youngkin.

03/18/2025

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem. The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include: A new name that reflects the commitment of Roanoke Blacksburg

03/14/2025

CEL-SCI’s Head and Neck Cancer Study Clears FDA Review, Eyes Commercialization Partners

CEL-SCI Corporation announced that a third-party study published on March 6, 2025 in JAMA Oncology titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial” provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression